GRIMALDI EUROMED SPA

Their core work

Grimaldi Euromed is a commercial maritime shipping operator — part of the Grimaldi Group, one of Europe's largest ro-ro and passenger ferry networks — that brings live port and vessel infrastructure to EU clean transport research as an industrial end-user and demonstration partner. Their real-world contribution to H2020 projects is access to operational Mediterranean shipping routes and port facilities, providing the kind of at-scale validation environment that laboratory partners cannot offer. In LeanShips they supported research into low-emission and methanol-fuelled vessels, while in H2Ports they moved into active deployment of hydrogen and fuel cell technologies within port operations. Their value to research consortia is essentially industrial credibility and operational testbed access, not primary research capability.

What they specialise in

How they've shifted over time

Their first H2020 involvement (LeanShips, 2015-2019) was broad and vessel-centric — methanol as alternative fuel, green shipping generally, retrofitting existing fleets for ecological improvement and economic efficiency. By 2019 the focus had sharpened significantly: H2Ports is entirely about hydrogen and fuel cells in port infrastructure, including noise, emissions, and port-specific equipment. This mirrors the wider maritime industry trajectory away from incremental retrofitting toward hydrogen as the preferred zero-emission pathway for heavy transport.

Grimaldi Euromed is moving from general clean shipping toward hydrogen-specific port infrastructure, suggesting they are positioning their Mediterranean operations as early-adopter demonstration sites for zero-emission port technology.

How they like to work

They have not coordinated any H2020 projects, joining exclusively as participant or third party — the role of an industrial end-user validating technology rather than driving research agendas. Their two projects sat inside large pan-European consortia (64 unique partners across 14 countries), which is typical for transport innovation actions that require real-world testbeds. This makes them best suited for consortia that need a credible commercial maritime operator to demonstrate feasibility at scale, not a research-design partner.

Despite only two projects, Grimaldi Euromed has touched 64 unique consortium partners across 14 countries — a sign of the large, multi-stakeholder consortia common in maritime transport research. Their network is broadly European with no apparent concentration in a single research cluster.

What sets them apart

As part of the Grimaldi Group's Mediterranean operations, Grimaldi Euromed can offer something most research partners cannot: real commercial ferry and ro-ro routes as a living laboratory for clean fuel technologies. Their Palermo base gives access to Southern European and North African shipping lanes — a geography underrepresented in EU maritime research, which tends to concentrate on Northern and Western European ports. For any consortium needing to demonstrate hydrogen or alternative fuel technologies in actual commercial port or vessel operations at Mediterranean scale, they are a rare and credible industrial anchor.

Highlights from their portfolio

• H2Ports
  Their most substantive EU engagement — a funded participant role in a 2019-2025 project implementing hydrogen and fuel cell technologies directly in live port operations, representing a concrete step toward zero-emission maritime infrastructure.
• LeanShips
  Early mover in EU clean shipping research (2015-2019), contributing as an industrial third party to a broad consortium targeting near-zero emission vessel technologies including methanol and retrofitting.